CN113456726A - Tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof - Google Patents

Tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof Download PDF

Info

Publication number
CN113456726A
CN113456726A CN202110776364.9A CN202110776364A CN113456726A CN 113456726 A CN113456726 A CN 113456726A CN 202110776364 A CN202110776364 A CN 202110776364A CN 113456726 A CN113456726 A CN 113456726A
Authority
CN
China
Prior art keywords
parts
tea pigment
filtrate
pigment composition
filtering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110776364.9A
Other languages
Chinese (zh)
Inventor
郑涵
席宾
刘春颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tiankang Weiye Technology Co ltd
Flower Of Life Beijing Health Management Co ltd
Original Assignee
Beijing Tiankang Weiye Technology Co ltd
Flower Of Life Beijing Health Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tiankang Weiye Technology Co ltd, Flower Of Life Beijing Health Management Co ltd filed Critical Beijing Tiankang Weiye Technology Co ltd
Priority to CN202110776364.9A priority Critical patent/CN113456726A/en
Publication of CN113456726A publication Critical patent/CN113456726A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof, wherein the tea pigment composition comprises the following components: tea pigment, kudzu vine root, emblic leafflower fruit, tree peony bark, dandelion, white peony root, centella and picrorhiza rhizome, and has the advantages of regulating gastrointestinal functions, preventing and treating liver injury, along with remarkable effect and no toxic or side effect.

Description

Tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof.
Background
The liver is the largest and most important digestive gland in the human digestive system and has important digestive functions, and is also the main hematopoietic organ of fetus and the main metabolic organ and defense organ of human body, and it exerts its powerful defense and detoxification functions against many harmful factors generated by chemical poison and metabolism outside the human body. The hepatic cells have poor tolerance to hypoxia, so hepatic artery and portal vein provide abundant blood supply, and bile is carried by large and small bile ducts and blood vessels.
Chemical liver injury is liver injury caused by chemical hepatotoxic substances. These chemicals include alcohol, environmentally toxic chemicals and certain drugs.
Chemical substances can enter the liver through the portal vein of the gastrointestinal tract or systemic circulation for transformation, and thus the liver is vulnerable to toxic substances in the chemical substances. In the production process of both nature and human industry, some substances with toxicity to liver exist, which are called as "hepatotropic poisons", the poisons are generally susceptible in people, the incubation period is short, the pathological process is directly related to the infection dosage, and the hepatonecrosis, fatty deformation, liver cirrhosis and liver cancer of the liver can be caused to different degrees.
Most of the existing liver-protecting medicaments in the market have the defects of toxic and side effects, high price, single effect and the like, and limit the clinical use of the medicaments to a certain extent. Therefore, the development of liver-protecting drugs with good effect and small toxic and side effects is a problem to be solved urgently at present. Compared with chemical synthetic drugs, the natural product has the advantages of multiple ways, various targets, low toxic and side effects and the like, so that more and more researchers focus on the natural product for preventing and treating liver injury.
In addition, the gastrointestinal tract is also an important digestive organ of the human body, and includes digestion, absorption and secretion, and immune functions. The main physiological functions of the gastrointestinal tract are to ingest, transport and digest food, absorb nutrition and excrete waste, the food is subjected to a series of complex digestion and decomposition processes in the gastrointestinal tract to become small molecular substances, the small molecular substances are absorbed by the intestinal tract, the food is processed by the liver to become in-vivo substances for the utilization of the tissues of the whole body, and the rest residues which are not absorbed and have no nutritive value form excrement to be discharged out of the body.
Digestive breakdown of food ingredients in the gastrointestinal tract requires enzymatic reactions involving hydrolases secreted by the pancreas, gastrointestinal glands, bile secreted by the liver, and enterobacterial enzymes. Digestion and absorption of food is a very complex process involving the exocrine and endocrine glands of the gastrointestinal tract, the motility of the gastrointestinal tract, the regulation of neurohumoral, the blood and lymphatic circulation and the interrelationship and close coordination between them, and any one of them is destroyed to cause gastrointestinal diseases. Wherein the absorption of gastrointestinal tract mucous epithelium, glandular secretion function and gastrointestinal tract smooth muscle contraction process are main reasons causing gastrointestinal tract diseases.
Chinese patent application CN102228551A discloses a traditional Chinese medicine composition for preventing and treating gastric mucosal injury and a preparation method thereof, wherein the traditional Chinese medicine composition contains active ingredients prepared from the following traditional Chinese medicines in parts by weight: 24-65 parts of astragalus membranaceus, 18-40 parts of poria cocos, 5-26 parts of dandelion, 3-15 parts of fructus evodiae, 3-21 parts of radix angelicae and 0.5-9 parts of calcined oyster. The traditional Chinese medicine composition for preventing and treating gastric mucosa injury provided by the invention has the effects of tonifying qi and spleen, clearing heat and eliminating dampness, and lowering adverse qi and harmonizing stomach by combining the medicines, so that the effect of protecting gastric mucosa is achieved. Tests prove that the pharmaceutical composition provided by the invention can prevent and treat gastric mucosal diseases. However, the traditional Chinese medicine composition has a single effect, and the prevention and treatment effect on liver injury needs to be improved.
Chinese patent application CN102727662A discloses a tea pigment capsule with functions of preventing and treating chemical liver injury and coordinating intestines and stomach, which is prepared by mixing radix Puerariae, fructus Phyllanthi, cortex moutan, tea pigment, starch and magnesium stearate in proportion, weighing radix Puerariae, fructus Phyllanthi and cortex moutan, placing in an extraction tank, and filtering the extractive solution; adding water into filter residues, heating, refluxing and extracting for 1-1.5 hours, filtering, combining filtrates, standing, and taking supernate for later use; placing in a concentration tank to obtain thick extract; drying, pulverizing, sieving, and drying to obtain dry extract; pulverizing the dry extract in a pulverizer, and sieving with a 80-mesh sieve to obtain fine powder A; pulverizing tea pigment in a pulverizer, and sieving with 80 mesh sieve to obtain fine powder B; sieving starch and magnesium stearate with 80 mesh sieve to obtain fine powder C; mixing the A, B, C to obtain total mixed powder; and finally, filling the total mixed powder into capsules. The traditional Chinese medicine is refined by traditional Chinese medicines, has no toxic or side effect, and is suitable for people with gastric mucosa injury and chemical liver injury to take. However, the effect of the tea pigment capsule in preventing and treating chemical liver injury and regulating gastrointestinal functions needs to be further improved.
Therefore, it is very necessary to develop a tea pigment composition having the functions of regulating the gastrointestinal functions and preventing and treating liver damage, which can solve the above technical problems.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a tea pigment composition which has obvious effects of coordinating gastrointestinal functions and preventing and treating liver injury and has no toxic or side effect and application thereof.
The invention is realized by the following technical scheme:
a tea pigment composition comprises the following components: tea pigment, radix Puerariae, fructus Phyllanthi, cortex moutan, herba Taraxaci, radix Paeoniae alba, herba Centellae and rhizoma picrorhizae.
Preferably, the tea pigment composition comprises the following components in parts by weight: 15-30 parts of tea pigment, 15-30 parts of kudzu root, 14-20 parts of emblic leafflower fruit, 10-16 parts of tree peony bark, 7-12 parts of dandelion, 3-9 parts of white peony root, 4-8 parts of centella and 6-13 parts of picrorhiza rhizome.
The invention also relates to a preparation process of the tea pigment composition, which comprises the following steps:
(1) decocting radix Puerariae, herba Taraxaci and herba Centellae with water, and filtering to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan in water, and filtering to obtain residue A and filtrate 2;
(3) mixing the filter residue A with radix paeoniae alba and rhizoma picrorhizae, adding a solvent A for extraction, and filtering to obtain a filtrate 3;
(4) concentrating filtrate 1, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
Preferably, step (1) comprises the steps of: decocting radix Puerariae, herba Taraxaci and herba Centellae with 4-8 times of water for 1-2 times, each for 2-3 hr, and filtering to obtain filtrate 1.
Preferably, the step (2) comprises the steps of: decocting fructus Phyllanthi and cortex moutan with 4-8 times of water for 1-2 times, each for 2-3 hr, and filtering to obtain residue A and filtrate 2.
Preferably, the solvent A in the step (3) is a mixed solvent of 60-80% ethanol, n-butanol and cyclohexane, and the volume ratio of the three is 3-5:1-2: 1.
Preferably, the filter residue A is mixed with the white paeony root and the rhizoma picrorhizae, 3-6 times of the solvent A is added for extraction for 1-2 times, each time lasts for 1-2 hours, the extraction temperature is 40-60 ℃, filtration is carried out, and the filtrate 3 is obtained after combination.
More preferably, the preparation process of the tea pigment composition comprises the following steps:
(1) decocting radix Puerariae, herba Taraxaci and herba Centellae with 4-8 times of water for 1-2 times, each for 2-3 hr, and filtering to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan with 4-8 times of water for 1-2 times (each for 2-3 hr), and filtering to obtain residue A and filtrate 2;
(3) mixing the filter residue A with radix Paeoniae alba and rhizoma picrorhizae, adding 3-6 times of solvent A (the solvent A is a mixed solvent of 60-80% ethanol, n-butanol and cyclohexane, and volume ratio of the solvent A to the solvent A is 3-5:1-2:1), extracting for 1-2 times, each time for 1-2 hr, at 40-60 deg.C, filtering, and mixing to obtain filtrate 3;
(4) concentrating filtrate 1, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
The invention also relates to a preparation which comprises the tea pigment composition or the tea pigment composition prepared by the preparation process.
Preferably, the preparation also comprises starch, magnesium stearate and other auxiliary materials.
More preferably, the formulation is of the type that is a capsule.
The invention also relates to the application of the tea pigment composition or the tea pigment composition prepared by the preparation process or the preparation in preparing medicines for coordinating gastrointestinal functions and preventing and treating liver injury.
The invention has the beneficial effects that:
the composition of the tea pigment composition is optimized, the components have a synergistic effect, particularly the synergistic effect among the kudzuvine root, the dandelion and the centella is obvious, and the effects of regulating the gastrointestinal function and preventing and treating liver injury of the product are obviously improved.
The invention optimizes the preparation process of the product, and the kudzu root, the dandelion and the centella are mixed and decocted, thereby being beneficial to further exerting the synergistic effect of the kudzu root, the dandelion and the centella.
In addition, the inventor finds that the effect of regulating intestines and stomach and preventing and treating liver injury of the product can be obviously improved compared with the effect of extracting the white paeony root and the picrorhiza rhizome separately by mixing and extracting the filter residue A after extracting the emblic leafflower fruit and the tree peony bark, the white paeony root and the picrorhiza rhizome.
In addition, the invention optimizes the solvent composition in the extraction process and further improves various effects of the product.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are illustrative only and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Example 1
The tea pigment composition comprises the following components in parts by weight: 15 parts of kudzu root, 14 parts of emblic leafflower fruit, 10 parts of tree peony bark, 15 parts of tea pigment, 7 parts of dandelion, 3 parts of white peony root, 4 parts of centella and 6 parts of picrorhiza rhizome.
The preparation process of the tea pigment composition comprises the following steps:
(1) decocting radix Puerariae, herba Taraxaci and herba Centellae with 4 times of water for 1 time for 3 hr, and filtering to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan with 4 times of water for 1 time for 3 hr, and filtering to obtain residue A and filtrate 2;
(3) mixing the filter residue A with radix Paeoniae alba and rhizoma picrorhizae, adding 3 times of solvent A (the solvent A is a mixed solvent of 6% ethanol, n-butanol and cyclohexane at a volume ratio of 3:1:1) and extracting for 1 time for 2h at 40 deg.C, filtering, and mixing to obtain filtrate 3;
(4) concentrating filtrate 1, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
Example 2
The tea pigment composition comprises the following components in parts by weight: 30 parts of kudzuvine root, 20 parts of emblic leafflower fruit, 16 parts of tree peony bark, 30 parts of tea pigment, 12 parts of dandelion, 9 parts of white paeony root, 8 parts of asiatic centella and 13 parts of figwortflower picrorhiza rhizome.
The preparation process of the tea pigment composition comprises the following steps:
(1) decocting radix Puerariae, herba Taraxaci and herba Centellae with 8 times of water for 2 times (2 hr each time), and filtering to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan with 8 times of water for 2 times, each for 2 hr, and filtering to obtain residue A and filtrate 2;
(3) mixing the filter residue A with radix Paeoniae alba and rhizoma picrorhizae, adding 6 times of solvent A (the solvent A is a mixed solvent of 80% ethanol, n-butanol and cyclohexane at a volume ratio of 5:2:1), extracting for 2 times (1 hr each time), filtering at 60 deg.C, and mixing to obtain filtrate 3;
(4) concentrating filtrate 1, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
Example 3
The tea pigment composition comprises the following components in parts by weight: 20 parts of kudzu root, 17 parts of emblic leafflower fruit, 13 parts of tree peony bark, 20 parts of tea pigment, 9 parts of dandelion, 6 parts of white peony root, 6 parts of centella and 10 parts of picrorhiza rhizome.
The preparation process of the tea pigment composition comprises the following steps:
(1) decocting radix Puerariae, herba Taraxaci and herba Centellae with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain residue A and filtrate 2;
(3) mixing the filter residue A with radix Paeoniae alba and rhizoma picrorhizae, adding 4 times of solvent A (the solvent A is a mixed solvent of 70% ethanol, n-butanol and cyclohexane at a volume ratio of 4:1.5:1), extracting for 2 times (1.5 hr for each time), extracting at 50 deg.C, filtering, and mixing to obtain filtrate 3;
(4) concentrating filtrate 1, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
Comparative example 1
The method is different from the embodiment 3 only in that 20 parts of kudzuvine root are replaced by 12 parts of dandelion and 8 parts of centella asiatica, and the other conditions are the same, specifically as follows:
the tea pigment composition comprises the following components in parts by weight: 17 parts of emblic leafflower fruit, 13 parts of tree peony bark, 20 parts of tea pigment, 21 parts of dandelion, 6 parts of white peony root, 14 parts of centella asiatica and 10 parts of rhizoma picrorhizae.
The preparation process of the tea pigment composition comprises the following steps:
(1) decocting herba Taraxaci and herba Centellae with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain residue A and filtrate 2;
(3) mixing the filter residue A with radix Paeoniae alba and rhizoma picrorhizae, adding 4 times of solvent A (the solvent A is a mixed solvent of 70% ethanol, n-butanol and cyclohexane at a volume ratio of 4:1.5:1), extracting for 2 times (1.5 hr for each time), extracting at 50 deg.C, filtering, and mixing to obtain filtrate 3;
(4) concentrating filtrate 1, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
Comparative example 2
The differences from the embodiment 3 are that 9 parts of dandelion and 6 parts of centella are replaced by 15 parts of kudzuvine root, and the other conditions are the same, and the method specifically comprises the following steps:
the tea pigment composition comprises the following components in parts by weight: 35 parts of kudzuvine root, 17 parts of emblic leafflower fruit, 13 parts of tree peony bark, 20 parts of tea pigment, 6 parts of white paeony root and 10 parts of figwortflower picrorhiza rhizome.
The preparation process of the tea pigment composition comprises the following steps:
(1) decocting radix Puerariae with 6 times of water for 2 times, each for 2.5 hr, filtering, and mixing to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain residue A and filtrate 2;
(3) mixing the filter residue A with radix Paeoniae alba and rhizoma picrorhizae, adding 4 times of solvent A (the solvent A is a mixed solvent of 70% ethanol, n-butanol and cyclohexane at a volume ratio of 4:1.5:1), extracting for 2 times (1.5 hr for each time), extracting at 50 deg.C, filtering, and mixing to obtain filtrate 3;
(4) concentrating filtrate 1, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
Comparative example 3
The difference from the example 3 is that in the preparation process of the tea pigment composition, the kudzu root, the dandelion and the centella are extracted separately, and the other conditions are the same, specifically as follows:
the preparation process of the tea pigment composition comprises the following steps:
(1) decocting radix Puerariae with 6 times of water for 2 times, each for 2.5 hr, filtering, and mixing to obtain filtrate 1-1;
(2) decocting herba Taraxaci and herba Centellae with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain filtrate 1-2;
(3) decocting fructus Phyllanthi and cortex moutan with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain residue A and filtrate 2;
(4) mixing the filter residue A with radix Paeoniae alba and rhizoma picrorhizae, adding 4 times of solvent A (the solvent A is a mixed solvent of 70% ethanol, n-butanol and cyclohexane at a volume ratio of 4:1.5:1), extracting for 2 times (1.5 hr for each time), extracting at 50 deg.C, filtering, and mixing to obtain filtrate 3;
(5) concentrating filtrate 1-1, filtrate 1-2, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
Comparative example 4
The difference from the example 3 is that in the preparation process of the tea pigment composition, the filter residue A, the white paeony root and the picrorhiza rhizome are separately extracted, and the other conditions are the same, specifically as follows:
the preparation process of the tea pigment composition comprises the following steps:
(1) decocting radix Puerariae, herba Taraxaci and herba Centellae with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan with 6 times of water for 2 times (2.5 hr each time), filtering, and mixing to obtain residue A and filtrate 2;
(3) extracting residue A with 4 times of solvent A (the solvent A is a mixed solvent of 70% ethanol, n-butanol and cyclohexane at a volume ratio of 4:1.5:1) for 2 times (each time for 1.5 hr), filtering at 50 deg.C, and mixing to obtain filtrate 3-1;
(4) mixing radix Paeoniae alba and rhizoma picrorhizae, adding 4 times of solvent A (the solvent A is a mixed solvent of 70% ethanol, n-butanol and cyclohexane at a volume ratio of 4:1.5:1) and extracting for 2 times (each time for 1.5 hr), at 50 deg.C, filtering, and mixing to obtain filtrate 3-2;
(5) concentrating filtrate 1, filtrate 2, filtrate 3-1, and filtrate 3-2 respectively, drying, and mixing with tea pigment.
Comparative example 5
The difference from the example 3 is only that the composition of the solvent A is different, the solvent A is a mixed solvent of 70% ethanol, n-butanol and cyclohexane, the volume ratio of the three is 1.5:4:1, and the rest conditions are the same.
Test example 1 prevention and treatment of acute gastric mucosal injury
Experimental animals: SD male healthy rats, 160-180 g, 8 per group were selected.
Experimental dosage of test sample: 135mg/kg & BW per day, and normal saline as solvent, wherein the mass-volume ratio of the test sample to the normal saline is 0.0135g/mL, namely the intragastric administration dosage is 10mL/kg & BW per day.
Experimental equipment and reagents: dissecting instrument, vernier caliper, alcohol.
Acute gastric mucosal injury model: animals were randomized into control and test groups. The control group was given physiological saline, and all animals were strictly fasted for 24 hours (without water deprivation) 30 days after the gavage of each group, during which time the administration of the test substance was also prohibited. After the test is finished, the test object is perfused for 1 hour on the day of experiment, then 1.0mL of absolute ethanol is perfused for each group, animals are sacrificed after 1 hour, the whole stomach is exposed, pylorus is tied, the stomach is taken out and fixed in 10% formaldehyde solution for 20 minutes, then the stomach is cut along the greater curvature of the stomach, the content of the stomach is cleaned by normal saline, the gastric mucosa is unfolded, and the degree of damage to the gastric mucosa is measured by a vernier caliper.
Vernier caliper measurement of degree of gastric mucosal damage: cutting the fixed stomach along the greater curvature of the stomach, washing the contents of the stomach, unfolding the gastric mucosa, and measuring the area (accurate to 0.01mm) of a bleeding strip by using a vernier caliper, wherein the injury of the gastric mucosa is represented by strip bleeding of the mucosa in the glandular and gastric regions, and the area of the bleeding strip is used as an evaluation index of the injury degree.
The test results are shown in table 1.
TABLE 1
Test sample Damaged area of gastric mucosa (mm)2)
Control group 342.71±136.01a
Example 1 146.09±112.48b
Example 2 149.58±93.26b
Example 3 141.32±99.25b
Comparative example 1 185.35±103.47c
Comparative example 2 178.16±94.56c
Comparison ofExample 3 169.47±82.18c
Comparative example 4 166.63±79.83c
Comparative example 5 162.80±74.91c
a. b, c different letters indicate that there is a significant difference between the groups.
In addition, there was no significant difference in body weight average for each group of rats during the test.
Test example 2 prevention and treatment of liver injury test
Experimental animals: male mice, 18-22 g, were selected, 10 per group.
Experimental dosage of test sample: 270mg/kg & BW per day, distilled water as solvent to prepare the test sample, the mass-volume ratio of the test sample to the distilled water is 0.027g/mL, namely the daily gavage dose is 10mL/kg & BW.
Molding: the model is made according to the method of 'carbon tetrachloride liver injury model' in 'health food inspection and evaluation technical Specification', and the model making mode is gastric perfusion. The test sample was administered for 30 days, and the control group was administered with distilled water.
On day 30 of the experiment, animals in each group were fasted overnight for 16 hours and CCl was administered to each group by gavage once4Mouse CCl4The gavage concentration is 1%, the gavage amount is 5mL/kg & BW (equivalent to CCl)4At a dose of 80mg/kg BW), the test groups continued to administer the test samples until the end of the experiment (and CCl)4Gavage interval 4 hours or more). Administration of CCl4Thereafter, the animals were sacrificed at 24 hours, and blood was taken to separate serum and determine ALT and AST. The results are shown in Table 2.
TABLE 2
Test sample ALT(U/L) AST(U/L)
Control group 174.52±36.78a 161.69±18.41a
Example 1 124.81±19.04b 116.01±21.82b
Example 2 128.47±28.37b 115.56±13.52b
Example 3 122.35±13.27b 112.38±14.17b
Comparative example 1 152.94±20.46c 135.47±24.96c
Comparative example 2 148.26±33.16c 137.34±28.35c
Comparative example 3 145.68±24.45c 133.12±20.14c
Comparative example 4 140.03±18.93c 129.73±13.07c
Comparative example 5 138.16±16.48c 125.25±11.28c
a. b, c different letters indicate that there is a significant difference between the groups.
The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.

Claims (10)

1. The tea pigment composition is characterized by comprising the following components: tea pigment, radix Puerariae, fructus Phyllanthi, cortex moutan, herba Taraxaci, radix Paeoniae alba, herba Centellae and rhizoma picrorhizae.
2. The tea pigment composition according to claim 1, comprising the following components in parts by weight: 15-30 parts of tea pigment, 15-30 parts of kudzu root, 14-20 parts of emblic leafflower fruit, 10-16 parts of tree peony bark, 7-12 parts of dandelion, 3-9 parts of white peony root, 4-8 parts of centella and 6-13 parts of picrorhiza rhizome.
3. A process for preparing the tea pigment composition according to claim 1 or 2, comprising the steps of:
(1) decocting radix Puerariae, herba Taraxaci and herba Centellae with water, and filtering to obtain filtrate 1;
(2) decocting fructus Phyllanthi and cortex moutan in water, and filtering to obtain residue A and filtrate 2;
(3) mixing the filter residue A with radix paeoniae alba and rhizoma picrorhizae, adding a solvent A for extraction, and filtering to obtain a filtrate 3;
(4) concentrating filtrate 1, filtrate 2 and filtrate 3 respectively, drying, and mixing with tea pigment.
4. The production process according to claim 3, wherein the step (1) comprises the steps of: decocting radix Puerariae, herba Taraxaci and herba Centellae with 4-8 times of water for 1-2 times, each for 2-3 hr, and filtering to obtain filtrate 1.
5. The production process according to claim 3, wherein the step (2) comprises the steps of: decocting fructus Phyllanthi and cortex moutan with 4-8 times of water for 1-2 times, each for 2-3 hr, and filtering to obtain residue A and filtrate 2.
6. The preparation process according to claim 3, wherein the solvent A is a mixed solvent of 60-80% ethanol, n-butanol and cyclohexane in a volume ratio of 3-5:1-2: 1.
7. The production process according to claim 3, wherein the step (3) comprises the steps of: mixing the residue A with radix Paeoniae alba and rhizoma picrorhizae, adding 3-6 times of solvent A, extracting for 1-2 times, each time for 1-2 hr, at 40-60 deg.C, and filtering to obtain filtrate 3.
8. A formulation comprising the tea pigment composition according to any one of claims 1 to 2 or the tea pigment composition prepared by the process according to any one of claims 3 to 7.
9. The preparation according to claim 8, which further comprises starch, magnesium stearate and other auxiliary materials, and the preparation is preferably in the form of a capsule.
10. Use of the tea pigment composition according to any one of claims 1 to 2 or the tea pigment composition prepared by the preparation process according to any one of claims 3 to 7 or the preparation according to any one of claims 8 to 9 for the preparation of a medicament for regulating gastrointestinal functions and preventing and treating liver damage.
CN202110776364.9A 2021-07-09 2021-07-09 Tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof Pending CN113456726A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110776364.9A CN113456726A (en) 2021-07-09 2021-07-09 Tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110776364.9A CN113456726A (en) 2021-07-09 2021-07-09 Tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof

Publications (1)

Publication Number Publication Date
CN113456726A true CN113456726A (en) 2021-10-01

Family

ID=77879380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110776364.9A Pending CN113456726A (en) 2021-07-09 2021-07-09 Tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof

Country Status (1)

Country Link
CN (1) CN113456726A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727662A (en) * 2011-04-15 2012-10-17 席宾 Tea pigment capsule having functions of preventing and treating chemical liver injury and conditioning functions of intestines and stomach

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727662A (en) * 2011-04-15 2012-10-17 席宾 Tea pigment capsule having functions of preventing and treating chemical liver injury and conditioning functions of intestines and stomach

Similar Documents

Publication Publication Date Title
CN109674958B (en) Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof
CN104436018A (en) Medicine for treating tumors and preparation method thereof
CN101199672A (en) Chinese medicine health care wine containing function of regulating human body immunity
CN101537159B (en) Traditional Chinese medicine composition and preparation method and application thereof
CN104013929A (en) Rheumatism pain relief medicine for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof
GB2219502A (en) Pharmaceutical composition containing bezoar bovis
CN102247479A (en) Antitumor strong medicine and preparation method thereof
KR20030055127A (en) Composition for anti-hyperlipidemia
CN102895387B (en) Kidney-yang-warming medicine composition, and preparation thereof and preparation method thereof
CN113456726A (en) Tea pigment composition with functions of coordinating intestines and stomach and preventing and treating liver injury and application thereof
CN108721431A (en) A kind of Chinese medicine composition of re-scheduling metal and its application
CN111437378B (en) Traditional Chinese medicine composition and medicine for preventing and treating chronic heart failure and preparation method thereof
CN104524359B (en) A kind of Chinese medicine composition, its preparation method and application
CN103961602B (en) The treatment Chinese medicine composition of chronic gastritis and tablet thereof and preparation method
CN1176708C (en) Capsule for treating psora
CN106581180B (en) A Chinese medicinal composition for treating abdominal pain, abdominal distention, and diarrhea
CN1163252C (en) Tianjian capsule and its preparing process
CN1861119B (en) Traditional Chinese medicine for treating rheumatosis and its preparation method
CN102327369B (en) Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof
CN1096687A (en) A kind of kidney invigorating and YANG supporting composition of liquid medicine and method for making thereof
CN105709193A (en) Artemisia argyi Levl-containing traditional Chinese medicine preparation for treating chronic enteritis and preparation method thereof
CN105250749A (en) Traditional Chinese medicine for treating thyroid adenoma and preparation method thereof
CN104940390A (en) Traditional Chinese medicine preparation for treating knee arthroncus and preparation method thereof
CN116270949A (en) Traditional Chinese medicine composition for reducing hyperuricemia and preparation method thereof
CN114796417A (en) Traditional Chinese medicine formula for reducing blood sugar and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211001